Aortic valve replacement with mechanical or biological prosthesis with extracorporeal circulation is the goldstandard for the treatment of calcific aortic stenosis. Although the results are excellent with the conventional approach some elderly patients, with multiple high-risk comorbid conditions, reoperations and severe left ventricular dysfunction have high surgical risk. During the last years percutaneous techniques have been developed. The present study aim to analyse the literature, since the experimental development untill clinical application of this novel treatment in patients with high surgical risk aortic stenosis. Percutaneous implantation of aortic valve prosthesis is beeing done in some centers and the cardiovascular surgeon that treats valve disease should be involved in this development. Descriptors: Aortic valve stenosis. Aortic valve. Stents. SAADI, EK -Percutaneous aortic aortic valve Replacement: myth or reality? Rev Bras Cir Cardiovasc 2008; 23(1): 93-96 
INTRODUCTION
Calcific aortic stenosis affects 2% to 5% of elderly individuals. It is the leading cause of surgical valve replacement in the United States and Europe. Cardiac surgery using cardiopulmonary bypass and aortic valve replacement by either mechanical or biological prosthesis is the procedure of choice in these cases. Aortic valve replacement with cardiopulmonary bypass support presents very low mortality and low morbidity and only in special occasions presents high surgical risk. Conventional surgery provides symptomatic improvement and increased survival in most patients with low surgical risk [1] . This procedure is the gold-standard for stenosis and or aortic valve insufficiency. However, in elderly patients with associated diseases, undergoing reoperation and presenting with severe ventricular dysfunction, mortality can reach up to 50% [2, 3] .
In the last decade, new attempts with less invasive procedures have arisen, such as left ventricle apex bypass for aorta and aortic valvoplasty with a balloon catheter in attempting to treat high-risk surgical patients [4] [5] [6] [7] .
Percutaneous treatment of aortic valve diseases with implantation of valves by catheter with stents has been tested as an alternative method [8] [9] [10] [11] [12] [13] .
After having used with relative success the dilation balloon catheter to treat neonatal aortic stenosis, it was attempted in patients with calcific aortic stenosis with poor outcomes and was practically abandoned. From then on, the concept of nonsurgical valve replacement has evolved. Initially, it was applied to the pulmonary valve due to its easy access and because it tolerates more easily not so perfect results as aortic valve. After a short-period of animal experimentation [9] , the first stent implants using pulmonary valve were reported by Bonhoeffer et al. [14] , in 2000, in patients with right ventricle conduit dysfunction for pulmonary artery. Currently, more than 100 patients have been treated by the abovementioned authors with only one death related to the procedure and with good outcomes in this pediatric group of patients [15, 16] . Cribier et al. [17] , in 2002, performed the first human implantation of a balloon-expandable prosthetic aortic valve in patients with severe aortic stenosis who were considered inoperable due to associated comorbidities. Since then, reports describing this new technique have been shown the feasibility of this procedure [18] [19] [20] [21] [22] .
In the first procedures, the valves mounted within the stent were released into the aortic ring through an antegrade transseptal approach, but technically speaking, this procedure was difficulty, especially to place the valve adequately into the aortic ring; it has been abandoned. The retrograde access via femoral artery seems more logical, but one important limitation has been related to the condition of arterial access. Initially, 24F (French) sheaths or bigger were necessary to release the prostheses. Currently, in the 3 rd -generation of these devices, 18F introducers already exist. The peripheral vascular access in these elderly patients with aorto-iliac atherosclerotic occlusion or thin femoraliliac vessels is one of the problems to be overcome. Other problems related with the method are as follows: risk of calcic embolization during aortic valve pre-dilation, coronary artery ostia impairment, valved stent migration, paravalvular leak, hemolysis, low cardiac output in the moment of dilation and release, and low prosthesis durability.
It is difficult for all surgeons who have experience with patients presenting calcific aortic stenosis to imagine that it is possible pre-dilate these petrified valves. However, oppositely to surgical logic, in the last three years some experimental studies have been published and early clinical experience showed that this is a feasible procedure and can be extended to the mitral valve [23, 24] .
One alternative to retrograde arterial access has been the transapical catheter antegrade release by left ventricle through a beating-heart minithoracotomy. The University of British Columbia Group, Vancouver, Canada, published a clinical experience with excellent outcomes using this technique [25] .
Naturally, due to the rapid expansion and development of this field, much controversy has been brought up. With the purpose of establishing the real state-of-the-art and to normalize the indications to percutaneous valve implantationm the Society of Thoracic Surgeons (STS) and the American Association for Thoracic Surgery (AATS) together with the Society for Cardiovascular Angiography and Interventions (SCAI) have issued an official position statement [26] . This text alerts for precautions that should be taken in order to avoid these procedures indiscriminating use, pointing out that many critical questions remain unanswered, including the durability of the devices. It has been stressed that experimental technologies are not justifiable in patients in whose, there are no established and published guidelines with clear indication, or in situations of prophylactic surgery until effective and security data are being published in well-designed clinical trials.
Even with the abovementioned exceptions, the method has been used in some centers, employing experimental clinical protocols in patients with no condition to undergo conventional surgery, where two cardiovascular surgeons sign the term contra-indicating the open surgery.
The outcomes have been reasonable and with a great interest and investment from the companies, the fast technological advance in manufacturing valves and catheters should facilitate the procedure and improve the indications. Most valves are composed of three equine or bovine pericardium leaflets mounted onto balloonexpandable or self-expandable stainless steel stents or nitinol. Currently, more than 20 companies develop these valve replacements and Cribier-Edwards ® as well as CoreValve ® are already being used in clinical series regularly, either percutaneoulsy or transapically.
Self-expandable prosthesis system presents several potential advantages over balloon-expandable devices. Besides being theoretically associated to a lower paravalvular leak incidence, it allows to treat patients with aortic valve insufficiency as well. Another potential advantage would be the greater prosthesis durability, once the trauma caused to the valve leaflets related to the ballon dilation would be eliminated [18, 20, 21] .
In December 2005, Lamarche et al. [27] performed a percutaneous aortic valve implantation in Montreal, Canada, in a patient with critical aortic stenosis, ventricular dysfunction, and pulmonary fibrosis with contra-indication for conventional surgery. A self-expandable CoreValve (Paris, Frances) was implanted via arterial retrograde with femorofemoral CPB support. The patient had an uneventfully course and the authors directed our attention to the importance of the multidisciplinary approach in these cases. In 2006, Grube et al. [28] reported a series of 25 consecutive patients undergoing percutaneous aortic valve implantation with femorofemoral cardiopulmonary bypass support. In this study, the patients with symptomatic aortic stenosis and aortic valve area lower than 1 cm were considered for enrollment. CoreValve implantation was performed under general anesthesia with femorofemoral CBP support. Clinical follow-up and echocardiography were performed after the procedure and at 15 and 30 days after device implantation to evaluate short-term outcomes. A total of 25 symptomatic patients with several comorbidities (median logistic EuroScore, 11%) were enrolled. Procedural success was achieved in 21 (84%) patients. Successful device implantation resulted in a marked reduction in the aortic valve gradients (p < 0.0001). Major in-hospital cardiovascular and cerebral events occurred in 8 patients (32%), including mortality in 5 patients (20%). Among 18 patients with device success surviving to discharge, no adverse events occurred within 30 days after leaving the hospital.
The authors concluded that percutaneous implantation of the self-expanding CoreValve aortic valve prosthesis in high-risk patients is feasible and, when successful, results in a marked reduction in the aortic valve gradients and clinical improvement in short-term. In 2007, a series with 50 consecutive patients treated percutaneously during 1 year-follow-up was published showing good outcomes in this period of time and greater therapeutic success in the last 25 cases, demonstrating the importance of a learning curve and a fast improvement of the devices [29] .
Currently, based on the aforementioned studies, we can assure that percutaneous aortic valve implantation is a procedure which is being applied, but it is still in the evaluation phase. In Brazil, the National Health Surveillance Agency (Anvisa) did not release any of these products yet. Much remains to be done, but this is a procedure has come to become the fashion. What we can discuss are the indications and which is the real space these less invasive procedures should occupy in clinical therapy of valve diseases. Despite the excellent outcome of the conventional valve surgery, science is advancing fast. We are living in exponential times. Cardiovascular surgeons involved in the treatment of valve diseases should be open to the introduction of groundbreaking methods, technologies, ideas, etc. Also, he/she should not get carried away and should always analyze the results in the light of well-conducted short and long term clinical trials. It is obviously that we must exert science rigorously to keep patients' safety. On the other hand, this is one more medicine field where the strict collaboration between the cardiovascular surgeon and the interventional cardiologist is critical to the patient's well-being.
